Compare ClearPoint Neuro Inc (CLPT) vs Enbridge Inc (ENB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ClearPoint Neuro Inc vs Enbridge Inc — how do they compare? ClearPoint Neuro Inc trades at $15.71 (market cap $478.63M), while Enbridge Inc trades at $56.11 (market cap $121.05B). The key difference: Enbridge Inc is far larger — about 252.9× ClearPoint Neuro Inc's market cap, and Enbridge Inc pays a 5.03% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| CLPT | ENB | |
|---|---|---|
Market Cap | $478.63M | $121.05B |
Sector | Health | Energy |
52-Week High | $29.60 | $58.04 |
52-Week Low | $8.66 | $44.59 |
Enterprise Value | $506.63M | $201.85B |
Dividend Yield | — | 5.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $16.51, down 5.66% on the day, with a bullish technical signal from moving averages but negative profitability. The company reported record Q1 2026 revenue of $36.97M with 25% organic device growth, though it missed EPS estimates with a $0.32 loss. Recent FDA clearance for the Velocity Alpha surgical drill and a partnership with Sungkyunkwan University highlight expansion efforts in neurosurgical navigation and drug delivery.
Outlook remains speculative with 100% analyst buy ratings anticipating gene therapy commercialization upside, but high execution and regulatory risks persist amid consistent losses and negative margins. The stock's valuation at 11.31x sales reflects growth expectations, yet cash burn from operations requires careful monitoring of financing sustainability.
Enbridge (ENB) trades at $55.07, up 0.75% today, with a bullish technical signal from moving averages. The company reported strong revenue growth to $65.19 billion in 2025, with net income of $7.49 billion, though it missed Q3 2025 EPS estimates. Analyst sentiment is balanced with a 48% buy rating, and the stock offers a dividend yield supported by over $28 billion in growth projects. Recent news highlights its role in energy infrastructure and AI-driven power demand.
Outlook is cautiously optimistic due to solid cash flow and dividend sustainability, but risks include high debt levels and sensitivity to energy markets. The stock presents a value opportunity for income-focused investors, with earnings on July 31, 2026, as a key near-term catalyst.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →About Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.
Read more on ENB →
